A detailed history of Barclays PLC transactions in Evolus, Inc. stock. As of the latest transaction made, Barclays PLC holds 93,662 shares of EOLS stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,662
Previous 93,662 -0.0%
Holding current value
$1.02 Million
Previous $1.52 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$10.66 - $17.48 $727,150 - $1.19 Million
68,213 Added 268.04%
93,662 $1.52 Million
Q2 2024

Aug 14, 2024

SELL
$10.45 - $13.76 $179,092 - $235,818
-17,138 Reduced 40.24%
25,449 $276,000
Q1 2024

May 15, 2024

SELL
$9.99 - $14.91 $268,431 - $400,631
-26,870 Reduced 38.69%
42,587 $595,000
Q4 2023

Feb 15, 2024

BUY
$7.6 - $10.53 $377,438 - $522,951
49,663 Added 250.9%
69,457 $730,000
Q3 2023

Nov 07, 2023

BUY
$7.15 - $10.2 $27,806 - $39,667
3,889 Added 24.45%
19,794 $181,000
Q2 2023

Aug 03, 2023

SELL
$7.23 - $10.52 $14,929 - $21,723
-2,065 Reduced 11.49%
15,905 $115,000
Q1 2023

May 04, 2023

BUY
$7.81 - $11.05 $66,080 - $93,494
8,461 Added 88.98%
17,970 $152,000
Q4 2022

Feb 13, 2023

SELL
$6.52 - $8.95 $2,757 - $3,785
-423 Reduced 4.26%
9,509 $72,000
Q3 2022

Nov 03, 2022

SELL
$7.76 - $13.72 $105,854 - $187,154
-13,641 Reduced 57.87%
9,932 $80,000
Q2 2022

Aug 12, 2022

BUY
$10.22 - $13.94 $130,151 - $177,525
12,735 Added 117.5%
23,573 $274,000
Q1 2022

May 16, 2022

SELL
$5.22 - $11.78 $205,579 - $463,931
-39,383 Reduced 78.42%
10,838 $121,000
Q4 2021

Feb 14, 2022

BUY
$5.37 - $8.38 $85,232 - $133,007
15,872 Added 46.21%
50,221 $327,000
Q3 2021

Nov 09, 2021

BUY
$7.36 - $13.67 $184,986 - $343,581
25,134 Added 272.75%
34,349 $262,000
Q2 2021

Aug 13, 2021

SELL
$8.42 - $13.96 $75,653 - $125,430
-8,985 Reduced 49.37%
9,215 $117,000
Q1 2021

May 13, 2021

SELL
$3.2 - $16.51 $3,561 - $18,375
-1,113 Reduced 5.76%
18,200 $237,000
Q4 2020

Feb 11, 2021

BUY
$2.92 - $4.84 $27,097 - $44,915
9,280 Added 92.49%
19,313 $65,000
Q3 2020

Nov 12, 2020

SELL
$3.03 - $5.48 $6,017 - $10,883
-1,986 Reduced 16.52%
10,033 $39,000
Q2 2020

Aug 12, 2020

BUY
$3.53 - $6.17 $20,766 - $36,298
5,883 Added 95.88%
12,019 $64,000
Q1 2020

May 13, 2020

SELL
$3.53 - $12.21 $43,549 - $150,634
-12,337 Reduced 66.78%
6,136 $26,000
Q4 2019

Feb 10, 2020

BUY
$11.58 - $17.37 $57,749 - $86,624
4,987 Added 36.98%
18,473 $225,000
Q3 2019

Nov 14, 2019

SELL
$13.91 - $19.87 $66,225 - $94,601
-4,761 Reduced 26.09%
13,486 $210,000
Q2 2019

Aug 14, 2019

BUY
$13.19 - $28.36 $37,208 - $80,003
2,821 Added 18.29%
18,247 $266,000
Q1 2019

May 15, 2019

BUY
$12.43 - $28.91 $113,995 - $265,133
9,171 Added 146.62%
15,426 $348,000
Q4 2018

Feb 14, 2019

SELL
$10.57 - $19.29 $183,653 - $335,163
-17,375 Reduced 73.53%
6,255 $75,000
Q3 2018

Nov 14, 2018

BUY
$17.31 - $29.82 $310,229 - $534,434
17,922 Added 313.98%
23,630 $439,000
Q2 2018

Aug 14, 2018

BUY
$6.85 - $38.49 $29,886 - $167,931
4,363 Added 324.39%
5,708 $159,000
Q1 2018

May 15, 2018

BUY
$8.34 - $12.5 $11,217 - $16,812
1,345 New
1,345 $12,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $611M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.